Quidelortho Corporation · NASDAQ:QDEL

Quidelortho — Raymond James 47th Annual Institutional Investors Conference 2026

21 slides from Quidelortho's conference presentation, Mar 3, 2026

  1. Slide 1: Raymond James 47th Annual Institutional Investor Conference

    March 3, 2026 Raymond James 47th Annual Institutional Investor Conference Brian J. Blaser President & Chief Executive Officer © 2026 QuidelOrtho Corporation. All rights reserved. | 1

  2. Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures

    Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements: This presentation of QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are

  3. Slide 3: Diversified Pureplay IVD Leader With Durable Growth

    Diversified Pureplay IVD Leader With Durable Growth Advancing the power of diagnostics for a healthier future for all Across Highly Across Key Healthcare Recurring Regions Settings Revenue Molecular 1% Instruments 4% Labs 55% DS 2% North Latin America 9% America 55% JAPAC 11% IH 20% Recurring $2.7B

  4. Slide 4: Well Positioned to Take Advantage of Trends Driving Diagnostics Market

    Well Positioned to Take Advantage of Trends Driving Diagnostics Market Global aging Decentralization Growth in emerging Increased focus on population and of healthcare markets from health awareness, burden of chronic increased longevity, and disease investment preventive care © 2026 QuidelOrtho Corp

  5. Slide 5: Highly Differentiated in Key IVD Market Segments

    Highly Differentiated in Key IVD Market Segments Labs Immunohematology Point of Care & Molecular 1 55% FY25 Revenue 20% FY25 Revenue 23% FY25 Revenue  Innovative dry-slide chemistry technology  Global market leader in  A market leader in U.S. respiratory  A market leader in acute care and “STAT”

  6. Slide 6: Broad Global Product Portfolio

    Broad Global Product Portfolio Labs VITROS 5600 and VITROS 450 Chemistry System VITROS ECL Systems VITROS XT 7600 Systems  Expands addressable  Integrated systems offer  First new VITROS platform market and increases 5 * Global scalable and reliable since 2019, the successor opportunity for OUS #

  7. Slide 7: Broad Global Product Portfolio

    Broad Global Product Portfolio SOFIA Platform TRIAGE System QUICKVUE Point  Rapid, automated and  A market leader in Rapid Lateral-Flow Tests  A family of rapid, visually read, of Care & LIS connected with reliable cardiac, including the only POC CLIA-waived lateral-flow tests to produce Molecula

  8. Slide 8: Innovation to Accelerate Near-term Growth

    Innovation to Accelerate Near-term Growth Menu/Platform Expansion Automation/Informatics Molecular Diagnostics  High Sensitivity Troponin U.S. launch  Create efficiency and streamline  Planned acquisition of LEX Diagnostics workflows enables access to one of the fastest-growing  VITROS 450 Syste

  9. Slide 9: Multiple Initiatives for Fueling Long-term Growth

    Multiple Initiatives for Fueling Long-term Growth Growth Strategic Levers Partnerships License Agreements M&A Anchored by QO’s Strategic Pillars Cost Structure Delivering an Exceptional Improvement Customer New Experience Products/ Innovation  Access new revenue streams  Expand into near adjacenci

  10. Slide 10: Leadership Team

    Leadership Team Brian Blaser Phil McLellan President & Chief Executive Officer Chief Operations Officer Joseph Busky Jonathan Siegrist, Ph.D. Chief Financial Officer Executive Vice President of R&D & Chief Technology Officer Lee Bowman Bryan Hanson Chief Human Resources Officer Executive Vice Presid

  11. Slide 11: FY25 Financial Results & FY26 Guidance

    FY25 Financial Results & FY26 Guidance Financial Guidance4 FY 2026 Total Revenue Total Revenues (Reported) $2.7B – $2.9B5 $2.73B 1 Adjusted EBITDA $630M – $670M 5% y/y Adjusted EBITDA Margin 23.3% Adjusted EBITDA Adjusted Diluted EPS $2.00 – $2.42 $597M 2 Free Cash Flow $120M – $160M 22% Margin Assu

  12. Slide 12: Free Cash Flow Generation

    Free Cash Flow Generation Cash flow expected to gain momentum in 2026 and beyond $217M Growth (mid-point of FY26 guidance) Target 50% $140 run-rate FCF- Adj. EBITDA conversion 2H27 $(77) $(112) 2024 2025 2026 Free Cash Flow Free Cash Flow Free Cash Flow* *Represents the mid-point of the Company’s 20

  13. Slide 13: Capital Allocation Priorities

    Capital Allocation Priorities Cash Flow Profitability Debt Leverage  Commercial focus on  Companywide focus on highest growth, increasing FCF, including profitable markets management incentives tied to achievement  Cost-savings initiatives Companywide for facility consolidation,  Target 50% run-

  14. Slide 14: Unlocking Value

    Unlocking Value Diagnostics leader with global scale in ~$50B TAM 96% FY25 recurring revenue highly attractive and growing markets Target market segments Large global installed base growing MSD+ Highly differentiated solutions creating lifetime customer value Stable, Adjusted Predictable EBITDA Marg

  15. Slide 15: Thank you

    Thank you @® QuidelOrtho”

  16. Slide 16: Appendix

    Appendix © 2026 QuidelOrtho Corporation. All rights reserved. | 16

  17. Slide 17: Non-GAAP Adjustments

    Non-GAAP Adjustments Fiscal Year In millions FY 2025 FY 2024 Incremental depreciation on PP&E fair value adjustment $ 12.6 $ 20.8 Amortization of deferred cloud computing implementation costs 2.8 0.4 Accelerated depreciation 3.8 — Other adjustments 0.2 0.1 Cost of sales, excluding amortization of in

  18. Slide 18: FY Non-GAAP Reconciliation

    FY Non-GAAP Reconciliation Fiscal Year 2025 Fiscal Year 2024 In millions GAAP Adjustments (a) Non-GAAP GAAP Adjustments (a) Non-GAAP Gross profit $ 1,274.2 $ 19.4 $ 1,293.6 $ 1,286.5 $ 21.3 $ 1,307.8 Selling, marketing and administrative 746.3 (36.8) 709.5 766.8 (37.1) 729.7 Research and development

  19. Slide 19: Non-GAAP Reconciliations – Adjusted EBITDA

    Non-GAAP Reconciliations – Adjusted EBITDA Fiscal Year In millions FY 2025 FY 2024 Net loss $ (1,131.8) $ (2,052.0) Depreciation and amortization 442.0 453.4 Interest expense, net 177.6 163.5 Provision for (benefit from) income taxes 24.1 (79.5) Restructuring, integration and other charges 263.6 127

  20. Slide 20: Non-GAAP Reconciliations

    Non-GAAP Reconciliations Fiscal Year In millions FY 2025 FY 2024 Net cash provided by operating activities $105.2 $83.0 Less: Acquisitions of property, plant, equipment, investments, and 188.2 195.1 intangibles Proceeds from government assistance allocated to fixed assets (6.5) - Free Cash Flow $(76

  21. Slide 21: quidelortho.com

    ae SAMMI quidelortho.co

QuidelOrtho — Raymond James 47th Annual Institutional Investors Conference 2026 on 6ix